2 news · updated Jun 24, 2026

Employers Drop GLP-1

2026-06-23

Eli Lilly Says China Approval for Oral GLP-1 Pill Could Come by 2026

Eli Lilly executives state their oral GLP-1 drug orforglipron may gain China approval between late 2026 and early 2027. Rival Novo Nordisk also plans to seek approval soon as competition grows in the

reuters · 2026-06-23 23:36 UTC

2026-06-11

Some US Employers to Drop Coverage of GLP-1 Obesity Drugs in 2027 as Use Increases

Rising usage of GLP-1 obesity drugs prompts some US employers to drop coverage in 2027 despite lower unit prices from manufacturers like Novo Nordisk and Eli Lilly. Industry experts cite growing patie

reuters · 2026-06-11 03:03 UTC

Employers Drop GLP-1

Eli Lilly Says China Approval for Oral GLP-1 Pill Could Come by 2026

Some US Employers to Drop Coverage of GLP-1 Obesity Drugs in 2027 as Use Increases

Media coverage (2)

Related topics